Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Corvus Pharmaceuticals, Inc. (CRVS)

Corvus Pharmaceuticals Q2 net loss widens to $18.0 million; cash totals $215.2 million

Negative Impact 3 of 5 earnings Written later

Corvus Pharmaceuticals reported a second-quarter 2026 net loss of $18.0 million, up from $8.0 million a year earlier, as research and development expenses roughly doubled to $16.0 million. The company said its cash, cash equivalents and marketable securities of $215.2 million, up from $56.8 million at December 31, 2025, fund operations into the second quarter of 2028, and it reiterated enrollment in its Phase 3 and Phase 2 soquelitinib trials.

Key points

  • Q2 2026 net loss was $18.0 million, or $0.19 per share, versus $8.0 million, or $0.10 per share, in Q2 2025.
  • R&D expenses were $16.0 million for the quarter, up $8.1 million, mainly from higher clinical trial costs and personnel costs.
  • Cash, cash equivalents and marketable securities were $215.2 million at June 30, 2026, including about $189.4 million in net proceeds from a financing completed January 23, 2026.
  • The filing reports no revenue line for the quarter.

The filing

CompanyCorvus Pharmaceuticals, Inc. (CRVS)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:02 PM ET
Accession number0001171843-26-005317

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.